مباشر
FierceBiotechGSK walks away from $100M bet on Mersana's STING ADC, pauses mRNA bird flu shot programFierceBiotechWhich blockbuster is GSK gunning for next? CEO Miels is looking to oncologyPharmaVoiceRevolution’s on a pancreatic cancer winning streak. What comes next for the biotech?PharmaVoiceObesity drugmakers chase weight loss. Biohaven is betting on muscles.Endpoints NewsGSK CEO says team reorg could be in the cards pending upcoming Phase 3 readoutsEndpoints NewsMPM has collected three China drugs for its ‘best of both worlds’ strategyEndpoints NewsAstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacy10x Genomics NewsA Look At 10x Genomics (TXG) Valuation After The Atera Spatial Biology Platform Launch - simplywall.stRoche MediaClean-up costs at Roche Pharmaceutical's Clare site pass €150m - MSNFierceBiotechFDA unveils plan for real-time review of clinical trial data, with AstraZeneca and Amgen already on boardFierceBiotechFDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting10x Genomics NewsVanguard Portfolio Management reports 6.98M TXG shares (NASDAQ: TXG) - Stock Titan
PharmaVoice ٢٩ أبريل ٢٠٢٦

Obesity drugmakers chase weight loss. Biohaven is betting on muscles.

Obesity drugmakers chase weight loss. Biohaven is betting on muscles.

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.